Dragonfly Therapeutics

24 articles with Dragonfly Therapeutics

• 

  Merck and Dragonfly, Together Again

  11/24/2021

  Merck opted to license its second TriNKET immunotherapy candidate from Dragonfly Therapeutics. The option came one year after Merck licensed its first immunotherapy candidate.

• Dragonfly Therapeutics Announces Sixth Dragonfly Drug to be Licensed by Bristol Myers Squibb and Receipt of Milestone Payments Following First Patient Dosing of Two TriNKET™ Immunotherapies

  10/18/2021

  The company announces its sixth drug licensed by Bristol Myers Squibb, and the first patients enrolled and dosed in Phase 1 clinical trials evaluating its CC-96191 and  CC-92328 NK cell engager therapies in patients with hematologic malignancies.

• Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate

  1/12/2021

  Dragonfly to receive payment for the first Opt-In from AbbVie as part of a multi-target collaboration launched just over 1 year ago.

• Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program

  8/17/2020

  Agreement Includes DF6002, With Potential to Advance Treatment of Solid Tumors and Hematology Indications

• Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology

  11/20/2019

  Dragonfly Therapeutics ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced a multi-target research collaboration designed to advance a number of Dragonfly's novel NK cell engager-based immunotherapies for autoimmune and oncology indications.

• 

  Dragonfly Partners With AbbVie to Take on Autoimmune and Oncology Indications

  11/20/2019

  At the center of the agreement are Dragonfly’s novel NK cell engager-based immunotherapies.

• Dragonfly Therapeutics Adds World-Leading Cancer Immunotherapy Pioneer to its Scientific Advisory Board

  8/6/2019

  Dr. Alan Korman, renowned for his work leading to the development the first approved checkpoint inhibitor cancer therapies, joins Dragonfly's scientific team.

• Both Nobel Prize Winner and World-Leading Clinician Join Dragonfly Therapeutics' Scientific Leadership Team

  4/10/2019

  Dr. Allison joins Nobel Prize winner Harold Varmus, M.D., and an outstanding group of clinicians and scientists on Dragonfly's Scientific Advisory Board.

• MD Anderson Cancer Center and Dragonfly Therapeutics announce strategic collaboration to take new immunotherapy candidates into clinical trials

  1/15/2019

  The University of Texas MD Anderson Cancer Centerand Dragonfly Therapeutics, Inc., today announced a strategic collaboration to bring Dragonfly’s TriNKET™ (tri-specific natural killer cell engager therapy) immunotherapy drug candidates to patients in clinical trials beginning in 2019.

• Dragonfly Therapeutics Announces Celgene In-license of First Two TriNKET™ Immunotherapy Drug Candidates

  12/13/2018

  Celgene licenses two TriNKET™ immunotherapy drug candidates built by Dragonfly for $24m plus milestones and royalties

• Dragonfly Therapeutics Announces Expansion of its Strategic Collaboration with Celgene, Doubling the Number of Programs and Including Targets for Solid Tumor Indications

  11/14/2018

  Celgene receives options to double its access to Dragonfly candidate natural killer (NK) cell engager immunotherapies, expanding to a total of eight collaboration targets between the two companies, and broadening the collaboration to include solid tumor targets

• Dragonfly Therapeutics Adds World-Leading Cancer Immunotherapy Experts to its Scientific Advisory Board

  10/8/2018

  Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced the addition of world-leading cancer immunotherapy experts Dr. Elizabeth M. Jaffee, Dr. Suzanne Topalian, and Dr. Lewis Lanier, to its Scientific Advisory Board.

• 

  Dragonfly and Merck Strike $695 Million Deal for Solid Tumors

  10/1/2018

  Dragonfly Therapeutics struck a licensing agreement worth up to $695 million with Merck. Merck will license exclusive rights to Dragonfly’s TriNKET technology platform for a number of solid-tumor programs, the company announced today.

• Dragonfly Therapeutics Announces New Multi-Target Collaboration with Merck to Use Dragonfly's Proprietary TriNKET™ Platform to Develop Novel Drug Candidates for Patients with Solid Tumors

  10/1/2018

  Merck receives exclusive options to license a number of Dragonfly's candidate natural killer (NK) cell engager immunotherapies for solid tumor malignancies.

• Pioneer in Taking Immunotherapies Through the Clinic Joins Dragonfly Therapeutics as CMO

  1/29/2018

  Dr. Cuillerot will head clinical development of Dragonfly's novel Natural Killer cell-based immunotherapies.

• Dragonfly Appoints World Leader In NK Therapeutics As Chief Scientific Officer

  6/26/2017

• Disney-Backed Dragonfly Nabs $33 Million From Biotech Bestie Celgene

  6/13/2017

• Dragonfly Adds Natural Killer Cell-Based Cancer Immunotherapy Expert To Its Scientific Advisory Board

  5/23/2017

• Dragonfly Announces Head Of Biology

  5/16/2017

• Dragonfly Completes New Investment Round

  5/15/2017